Evidence map›Paper›PMID 41917310›Full record

ReviewAmerican journal of clinical dermatology2026

Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!

Luca Rapparini, Timila Assia Touhouche, Davide Fattore, Azael Freites-Martinez, Pauline Hirtz, Zoe Apalla, Emmanuelle Vigarios, Delphine Maret, Michela Starace, Vincent Sibaud

Abstract readReview
In one paragraph

Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Dermatologic Toxicities Induced by JAK Inhibitors.American journal of clinical dermatology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luca RappariniDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. luca.rapparini2@studio.unibo.it.ORCID http://orcid.org/0000-0002-4029-941X
Timila Assia TouhoucheOncodermatology-Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Davide FattoreSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Azael Freites-MartinezOncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain.
Pauline HirtzOncodermatology-Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Zoe ApallaFirst Department of Dermatology, Aristotle University of Thessaloniki, Thessaloníki, Greece.
Emmanuelle VigariosOral Medicine, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France.
Delphine MaretLaboratoire CAGT, Department of Dental Surgery, Université of Toulouse, Centre Hospitalier Universitaire, Toulouse, France.
Michela StaraceDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Vincent SibaudOncodermatology-Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing efficacy of oncological therapies has led to a rapidly growing population of cancer survivors, shifting clinical attention from acute treatment-related toxicities to long-term and late sequelae. Among these, dermatological sequelae represent some of the most visible and persistent consequences of cancer treatments and may significantly impair quality of life. Persistent alopecia, nail disorders, pigmentary alterations, chronic radiation-induced skin changes, scarring, vascular abnormalities, mucosal alterations, and secondary skin cancers may develop or persist long after treatment completion, acting as constant reminders of the cancer experience. These conditions are not only cosmetic; they may be associated with functional limitations, psychological distress, and altered body image, particularly in patients treated during childhood or adolescence. While the role of supportive oncodermatology during active cancer treatment is well established, structured dermatological care in the survivorship phase remains insufficiently developed. This narrative review provides a comprehensive overview of the main long-lasting dermatological adverse events associated with chemotherapy, radiotherapy, targeted therapies, immunotherapy, endocrine treatments, and hematopoietic stem cell transplantation. In addition, available restorative and corrective dermatological interventions are discussed, with a focus on improving long-term outcomes and patient well-being. Recognizing and managing dermatological sequelae is an essential component of modern survivorship care, and dermatologists should play a central role in multidisciplinary follow-up programs dedicated to cancer survivors.

Indexed as

Cancer SurvivorsDermatologyNeoplasmsSkin DiseasesAntineoplastic AgentsHealth Services Needs and DemandHematopoietic Stem Cell TransplantationHumansQuality of LifeRadiotherapyAntineoplastic Agents

Identifiers

PMID41917310
PMCPMC13171996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.